Herantis’ HER-096 Phase 1a clinical study in healthy volunteers is ongoing in Finland
The first-in-human clinical study with HER-096 will assess safety, tolerability, pharmacokinetic properties and blood-brain barrier penetration of subcutaneously administered single dose of HER-096. The randomized, double-blinded and placebo-controlled study aims to recruit around 60 healthy volunteer subjects. The topline data is expected by Q4-2023.
Successful completion of the study would represent a significant milestone for Herantis, and Herantis will then move on to study HER-096 in patients with Parkinson’s disease.
The Phase 1a study is conducted in Finland by the contract research organization Clinical Research Services Turku – CRST Oy (https://www.crst.fi/). More information about the ongoing study including the participation is available on CRST website (only in Finnish https://osallistulaaketutkimukseen.fi/kliininen-laaketutkimus-50-75-vuotiaille-c739/ ).
A more detailed description of the study is available at Clinicaltrials.gov (Study ID NCT05915247).